Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs
| Autor: | Lars Høj Markvardsen, Thomas Harbo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Pediatrics Mismatch negativity Chronic inflammatory demyelinating polyneuropathy Review Subcutaneous immunoglobulin Infusions Subcutaneous law.invention 03 medical and health sciences 0302 clinical medicine Subcutaneous Absorption Quality of life Randomized controlled trial law medicine Journal Article Humans Immunologic Factors In patient 030212 general & internal medicine Motor Neuron Disease business.industry Immunization Passive medicine.disease Treatment efficacy Immunoglobulin Isotypes Polyradiculoneuropathy Chronic Inflammatory Demyelinating Neurology Physical therapy Neurology (clinical) business 030217 neurology & neurosurgery Multifocal motor neuropathy |
| Zdroj: | Markvardsen, L H & Harbo, T 2017, ' Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs ', Journal of the Neurological Sciences, vol. 378, pp. 19-25 . https://doi.org/10.1016/j.jns.2017.04.039 |
| DOI: | 10.1016/j.jns.2017.04.039 |
| Popis: | Subcutaneous administration of immunoglobulin (SCIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) has been reported in several case reports and in a few randomized trials during the last decade. In this review we present the studies on SCIG in CIDP and MMN with special focus on the clinical effects. Moreover, the effect on quality of life, side effects to SCIG and the health economic perspectives are reviewed. Nine case studies, three randomized trials and six long-term, follow-up studies were identified. Most of the studies are conducted in patients switched from regular IVIG to SCIG treatment; one study involves treatment-naïve patients. The review shows that none of the studies have been powered to demonstrate an effect on disability. SCIG can maintain muscle strength for a period of 1 to 2years and ability seems preserved for a similar period. Quality of life is generally unchanged or improved after switch to SCIG and generalized side-effects seem fewer, whereas local reactions at the injection site occur. Health economic analyses favour SCIG at the doses used in the reviewed studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|